Science AI Journal
Medicine · Research topic

Open research questions in Pharmacology and Obesity Treatment

26 unresolved questions extracted from the limitations and future-work sections of 378 Pharmacology and Obesity Treatment papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • In addition, future research is required to identify the specific metabolites that modulate the gut-adipose axis through targeted quantification of fecal and serum microbial metabolites and verification of their associated signaling pathways. Although our results iden- tify a close correlation between increased Akkermansia abundance and the metabolic advantages of RLMCR, direct causal evidence is lacking.

    A novel solid beverage RLMCR prevents obesity-related metabolic disorders through the gut-adipose axis · 2026 · DOI

  • Incretin-based therapies, particularly tirzepatide, have emerged as promising treatments for obesity-related OSA following the SURMOUNT-OSA trial, demonstrating significant reductions in apnea–hypopnea index and cardiometabolic risk factors, though their effect in patients with T2DM remains unclear.

    Management of Obstructive Sleep Apnea in People with Type 2 Diabetes · 2026 · DOI

  • The circular utilization of traditional Chinese medicine residue waste is crucial for promoting the green development of the traditional Chinese medicine industry and environmental protection. The traditional treatment methods for such large amounts of biological waste have problems such as high cost, heavy pollution, and low resource utilization rate. The current research and practical hotspots have shifted toward using pretreatment techniques to destroy its complex structure, and combining it with biological fermentation technology for efficient and highvalue comprehensive utilization. The fermentation of herbal residues using probiotics represents an innovative approach that the need addresses two significant challenges simultaneously: for effective obesity treatments and the sustainable utilization of herbal medicine byproducts. This review has summarized compelling evidence that probiotic fermentation enhances the bioactive profiles, bioavailability, and therapeutic efficacy of herbal residues against obesity and its metabolic complications. The antiobesity effects of these fermented preparations operate through multiple complementary mechanisms, including gut microbiota inflammatory modulation, bile acid metabolism regulation, pathway modulation, and enhancement of intestinal barrier function. For example, studies have shown that oligosaccharides in Rehmannia glutinosa can significantly regulate gut microbiota. Its special structure can resist gastric enzyme digestion, selectively promote the proliferation of probiotics after reaching the intestine, and thus play a role in regulating lipid metabolism (136). Puerarin (137) can directly act on host cells, alter the integrity of intestinal epithelial cells in obese mice, and prevent obesity phenotype. Flavonoids can protect the intestinal epithelial cell barrier, reduce the absorption of microbial metabolites such as endotoxins, and promote the proliferation of probiotics. Has significant lipid-lowering effect (138). The integration of modern fermentation technologies with traditional herbal knowledge creates a powerful platform for developing novel, effective, and sustainable interventions for obesity management. Despite the promising results, several challenges impede fermented herbal residues in the widespread application of obesity management: I. Mechanistic has efficacy elucidation: While been demonstrated in experimental models, the precise molecular mechanisms and active metabolites responsible for the anti-obesity effects require further characterization.

    Probiotic-fermented herbal residues in obesity management: a review · 2026 · DOI

  • The differential weight loss response in subpopulations (e.g., individuals without diabetes showed more pronounced tirzepatide advantage over semaglutide in real-world data) has not been systematically characterized with respect to baseline metabolic status, insulin sensitivity, or genetic predictors of drug response in tirzepatide-treated cohorts.

    Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials · 2026 · DOI

  • Weight regain patterns after tirzepatide withdrawal observed in SURMOUNT-4 require detailed characterization of kinetics and biological mechanisms driving relapse. Specifically, comparative analysis of weight regain trajectories, changes in metabolic parameters, and appetite-regulating hormone dynamics post-discontinuation versus continued therapy needs systematic investigation.

    Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials · 2026 · DOI

  • The determinants of gastrointestinal adverse event severity and discontinuation risk at higher tirzepatide doses require mechanistic characterization. Current evidence documents that GI symptoms are dose-dependent and most frequent during escalation, but predictive factors for individual tolerability and strategies to mitigate tolerability-driven treatment discontinuation are not systematically evaluated.

    Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials · 2026 · DOI

  • The available literature relies heavily on indirect network meta-analyses for comparative effectiveness between tirzepatide and other anti-obesity medications. Direct head-to-head randomized trials comparing tirzepatide with agents beyond semaglutide (e.g., other GLP-1 receptor agonists, combination therapies) are limited and needed to establish comprehensive treatment algorithm positioning.

    Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials · 2026 · DOI

  • Real-world evidence comparing tirzepatide with semaglutide is limited to shorter observation periods (6 months in the cited ambulatory-care study) and lacks standardized documentation of dose-titration schedules and patient adherence patterns. Confirmation in larger populations under varied real-life dosing protocols is needed to validate trial findings in clinical practice.

    Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials · 2026 · DOI

  • Randomized controlled trial evidence for tirzepatide extends only to 176 weeks, while long-term safety and durability of weight loss effects beyond 5 years remain uncharacterized. Direct comparison with semaglutide has longer-term data available from the two-year STEP 5 trial, but equivalent extended follow-up data for tirzepatide are unavailable.

    Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials · 2026 · DOI

  • While previous studies have found the effectiveness of breadfruit leaf capsules in improving metabolic status among prediabetics, limited studies exist on their effectiveness in people with Diabetes Mellitus (DM).

    Effectiveness of Breadfruit Leaf Extract (Artocarpus altilis) in Improving Metabolic Syndrome (Mets) Components in Diabetes Mellitus Patients in Bone Regency - Indonesia · 2024 · DOI

  • Despite the increasingly appreciated link between obesity and a broad range of cardiovascular disease manifestations including atherosclerotic disease, heart failure, thromboembolic disease, arrhythmias, and sudden cardiac death, obesity has been underrecognized and sub-optimally addressed compared with other modifiable cardiovascular risk factors.

    Obesity and cardiovascular disease: an ESC clinical consensus statement · 2024 · DOI

  • Limited research has examined the relationship between different dietary modifications and body weight, LBM, and RMR.

    Impact of Diet Interventions for Weight Loss on Lean Body Mass and Resting Metabolic Rate: A Systematic Review · 2026 · DOI

  • Without concurrent assessment of bone density, muscle strength, and physical performance, it remains unclear whether observed reductions in lean mass reflect mean- ingful functional decline or largely benign changes in tissue composition.

    Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity · 2026 · DOI

  • Collectively, the findings highlight the ingredients biological versatility and contextual responsiveness across physiological systems, and suggest its prebiotic potential through alignment with ISAPPs definition of a prebiotic, supporting further investigation of specific mechanistic pathways.

    Supplementation with Arabinoxylan Dietary Fiber at Low Doses Produces Behavioral, Metabolic, and Gut Microbial Changes in Healthy, Overweight Adults: A Randomized Placebo-Controlled Trial · 2026 · DOI

  • The mechanisms of how sodium-glucose cotransporter 2 inhibitors affect substrate metabolism in prediabetic insulin-resistant individuals need expanded investigation beyond current randomized…

    Current Status of Weight Loss Therapy in Achieving Remission of Type 2 Diabetes Mellitus · 2026 · DOI

  • Lifestyle modification, through changes in eating and exercise behaviors, has long been a cornerstone of obesity treatment; however, there is a lack of evidence to fully demonstrate the role that lifestyle plays with the latest generation of OMMs compared to previous obesity pharmacotherapies.

    The Critical Role of Lifestyle With the Use of Contemporary Obesity Management Medications · 2025 · DOI

  • This finding suggests that clinicians need to monitor patients closely after bariatric surgery and that further exploration of the effects of bariatric surgery on antidepressant pharmacokinetic parameters is warranted.

    A Comparison of Duloxetine Plasma Levels in Postbariatric Surgery Patients Versus Matched Nonsurgical Control Subjects · 2013 · DOI

  • Thus, in the ten years since the passage of DSHEA, the dietary supplement industry remains controversial and a concern for consumer safety.

    Ephedra · 2005 · DOI

Most-cited papers in Pharmacology and Obesity Treatment

Most recent work

Find a gap in your own Pharmacology and Obesity Treatment sub-topic

This page shows what the Pharmacology and Obesity Treatment literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
26 open questions have been extracted from the limitations and future-work passages of 378 Pharmacology and Obesity Treatment papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.